General
Preferred name
FENOLDOPAM
Synonyms
FENOLDOPAM MESYLATE ()
FENOLDOPAM BROMIDE ()
Fenoldopam hydrochloride ()
SKF-82526 mesylate ()
Fenoldopam methanesulfonate ()
Corlopam mesylate ()
SKF 82526 ()
mesylate ()
SKF-82526, (-) ()
SKF-82526, (+) ()
Fenoldopam (mesylate) ()
Fenoldopam (methanesulfonate) ()
SKF-82526 (mesylate) ()
SKF 82526 (mesylate), Fenoldopam methanesulfonate, Corlopam mesylate ()
NSC-759860 ()
SK&F-82526J ()
SK-82526-J ()
Corlopam ()
Fenoldopam mesilate ()
Fendolopam mesylate ()
SK&F 82526-J ()
SK-82526 ()
Carlacor ()
SK&F-82526 ()
P&D ID
PD009713
CAS
181217-39-0
67227-56-9
95865-71-7
1092382-99-4
67227-57-0
Tags
natural product
drug
available
Approved by
FDA
First approval
1997
Drug Status
approved
Drug indication
Hypertension
Antihypertensive
Dopamine Agonist
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Radiolabeled studies show that about 90% of infused fenoldopam is eliminated in urine, 10% in feces.; Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Only 4% of the administered dose is excreted unchanged.
DESCRIPTION The approved drug fenoldopam is a racemic mixture of and stereoisomers. We show the non-isomeric structure to represent this mixture. Marketed formulations may contain fenoldopam mesylate (PubChem CID 49659). (GtoPdb)
DESCRIPTION Peripheral D1 dopamine receptor agonist (LOPAC library)
DESCRIPTION Selective D1-like partial agonist (Tocriscreen Total)
DESCRIPTION Fenoldopam hydrochloride is a selective partial agonist of dopamine D1 receptor (EC50 = 57 nM). It also acts as an α2-adrenoceptor antagonist in vitro (Ki = 15 - 25 nM). Fenoldopam can be used as a vasodilator and antihypertensive. (BOC Sciences Bioactive Compounds)
DESCRIPTION Potent and selective 5-HT2B and 5-HT2C antagonist; orally active (Tocris Bioactive Compound Library)
Cell lines
0
Organisms
4
Compound Sets
35
AdooQ Bioactive Compound Library
A11720
BOC Sciences Bioactive Compounds
fenoldopam-hydrochloride-cas-181217-39-0-item-119096
Cayman Chemical Bioactives
17629
ChEMBL Approved Drugs
CHEMBL1026
CHEMBL588
ChEMBL Drugs
CHEMBL1026
CHEMBL588
Concise Guide to Pharmacology 2017/18
939
Concise Guide to Pharmacology 2019/20
939
Concise Guide to Pharmacology 2021/22
939
Concise Guide to Pharmacology 2023/24
939
DrugBank
DB00800
DrugBank Approved Drugs
DB00800
DrugCentral
1153
DrugCentral Approved Drugs
1153
DrugMAP
DMFAOKP
DrugMAP Approved Drugs
DMFAOKP
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101653
Guide to Pharmacology
939
Ki Database
FENOLDOPAM
SKF-82526, (+)
SKF-82526, (-)
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1026
CHEMBL588
Mcule NIBR MoA Box Subset
MCULE-3764473965
MedChem Express Bioactive Compound Library
HY-B0735A
NCATS Inxight Approved Drugs
INU8H2KAWG
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
fenoldopam-mesylate
fenoldopam-corlopam
TargetMol Bioactive Compound Library
T6835
The Spectrum Collection
Tocris Bioactive Compound Library
1659
Tocriscreen Total
External IDs
76
Properties
(calculated by RDKit )
Molecular Weight
305.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
2
cLogP
2.73
TPSA
72.72
Fraction CSP3
0.25
Chiral centers
1.0
Largest ring
7.0
QED
0.61
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
D1
Pathway
GPCR/G protein
Neuronal Signaling
Apoptosis
Target
dopamine-1 receptor
Dopamine Receptor
Primary Target
D1 and D5 Receptors
MOA
Agonist
Dopamine D1 Agonists
Member status
member
Therapeutic Class
Antihypertensive Agents
Source data